Oocyte and embryo cryopreservation before gonadotoxic treatments: Principles of safe ovarian stimulation, a systematic review. (February 2022)

• Record Type: Journal Article
• Authors: Ozcan, Meghan CH; Snegovskikh, Victoria; Adamson, G David
• Is Part Of: Women's health. Volume 18(2022)
• Publication Date: 2022-02
• Subjects: cancer -- chemotherapy -- cryopreservation -- embryos -- fertility preservation -- oocytes -- safety; Gynecology -- Periodicals; Obstetrics -- Periodicals; Women -- Health and hygiene -- Periodicals; 618.05
• DOI: 10.1177/17455065221074886
• Languages: English
• ISSNs: 1745-5057

Abstract

Objective: Review the safety of fertility preservation through ovarian stimulation with oocyte or embryo cryopreservation, including cycle and medication options. Evidence review: A systematic review of peer-reviewed sources revealed 2 applicable randomized control trials and 60 cohort studies as well as 20 additional expert opinions or reviews. Results: The capacity for future family building is important for the majority of reproductive age people, despite life-altering medical or oncologic diagnosis. Modern fertility preservation generates a high rate of oocyte yield while utilizing protocols that can be started at multiple points in the menstrual cycle and suppressing supra-physiologic levels of estrogen. Finally, more than one quarter of fertility preservation patients will return to later utilize fertility services. Conclusion: For most patients, fertility preservation can safely be pursued and completed within 2 weeks without affecting disease severity or long-term survival.